Dr. Kewalramani oversees clinical medical affairs, drug safety and other related functions and is responsible for developing, advising and driving execution of Vertex’s clinical development programs.
Vertex captured my heart and imagination when I saw the opportunity to help create medicines that could potentially have a huge impact on people’s lives. I was especially impressed with our model of working in serious diseases where we have an excellent understanding of the underlying biology, because it gives us a higher chance of success when making the leap from the lab bench to a patient.
“Drug discovery is like a relay race – a race against time. Even before the Research team is ready to pass the baton to the clinical team, we are doing everything we can to clear the road ahead and remove obstacles so the transition is as fast and seamless as possible. For example, we include a small cohort of cystic fibrosis patients in our first-in-human studies to ensure what we see in healthy volunteers is recapitulated in patients. Throughout the race, we have strategically-placed “runners” – our subject-matter experts - where their skills and expertise can have the most impact.”